Tyme Technologies, Inc. (NASDAQ: TYME) (the “Company”), a clinical-stage biotechnology company developing cancer therapeutics, today announced that it had commenced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE